Theravance Biopharma

Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Theravance Biopharma excels in Q2 with strong sales growth

Theravance Biopharma delivered strong financial performance in Q2 2024, driven by robust sales of YUPELRI and Trelegy.
While facing challenges such as ongoing losses and R&D expenses, the company remains focused on innovation and operational efficiency.
With a solid cash position, key patent grants, and growth opportunities in new markets, Theravance is poised for future growth and value creation.
Investors can look forward to potential milestones and market expansion initiatives as Theravance continues to execute its strategic vision.

Theravance Biopharma reports strong Q3 performance and strategic growth plans

Theravance Biopharma (TBPH) delivered strong financial performance in Q3 2024, driven by robust sales growth of YUPELRI and TRELEGY, supported by strategic cost management.
The company's focus on unlocking shareholder value through a Strategic Review Committee and commitment to long-term innovation position it for sustainable growth.
While facing challenges in meeting sales milestones and managing expenses, Theravance has opportunities to leverage its product performance and financial stability for future success.
With a solid cash position and prudent financial planning, Theravance is poised to navigate challenges and capitalize on growth opportunities in the biopharmaceutical market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DUBLIN , April 29, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2024 financial results and provide a business update after market close on Monday, May 13, 2024. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm IST) that day.

Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024

AnaptysBio

Bitdeer Technologies Group

The stock market may have pulled back a bit from the all-time high reached late last month but the S&P 500 remains 7.4% higher in 2024. Technology stocks continue to be top performers with Super Micro Computer (NASDAQ: SMCI ) leading the way with a 216% gain so far.

BTIG Research Predicts Over 118% Rally for These 3 Stocks

Theravance Bio (TBPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength?

DUBLIN , April 10, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (the "Company") (NASDAQ: TBPH) today announced it will host a virtual KOL event on Thursday, May 23, 2024 from 10:00 AM to 11:30 AM ET, featuring Horacio Kaufmann, MD, FAAN (Felicia B. Axelrod Professor of Neurology and Professor of Medicine at New York University Grossman School of Medicine) and Italo Biaggioni, MD (Professor of Medicine and Pharmacology Director, Vanderbilt Autonomic Dysfunction Center), who will discuss the unmet need and current treatment landscape for MSA patients with symptomatic nOH.

Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?

Why Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report?

AirSculpt Technologies

Mondee Holdings Inc

The life of a bearish speculator can be dangerous and that's part of the appeal of short-squeeze stocks: you can make life miserable for those attempting to cynically extract profits from others' misery. At the most elemental level, I suppose it's like watching a lion eating a safari hunter.

Short-Squeeze Showdown: 3 Stocks Ready to Crush the Skeptics

Theravance's (TBPH) fourth-quarter earnings and revenues beat estimates. The company achieves profitability on an adjusted basis during the same time.

Theravance's (TBPH) Q4 Earnings & Revenues Surpass Estimates

Theravance Biopharma, Inc. (TBPH) Q4 2023 Earnings Call Transcript

Theravance Biopharma (TBPH) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to loss of $0.21 per share a year ago.

Theravance Biopharma (TBPH) Tops Q4 Earnings and Revenue Estimates

Q4 2023 YUPELRI® (revefenacin) net sales, recognized by Viatris, increased 9% from Q4 2022, reaching an all-time high of $60.6 million 1 Full Year 2023 Viatris Collaboration Revenue increased 18% to $57.2 million GAAP Net Loss of $8.5 million in Q4; Achieved goal of profitability on Non-GAAP basis in Q4 , with Non-GAAP Net Profit of $1.4 million 2 Completed $325 million capital return program, reducing shares outstanding by 37% Ampreloxetine investor event planned for Q2 2024 DUBLIN , Feb. 26, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced financial and operational results for the fourth quarter of 2023 and full-year ended December 31, 2023. "The Theravance team delivered a strong performance in 2023, having achieved our financial objectives in the fourth quarter and exceeded our aggressive annual goal for YUPELRI hospital growth," said Rick E Winningham, Chief Executive Officer.

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

DUBLIN , Feb. 14, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2023 financial results and provide a business update after market close on Monday, February 26, 2024. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm GMT) that day.

Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024

The heavy selling pressure might have exhausted for Theravance Bio (TBPH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -11.17% in 4 Weeks, Here's Why Theravance Bio (TBPH) Looks Ripe for a Turnaround

Theravance Biopharma shares fell more than 20% after the company reported that its therapeutic for chronic obstructive pulmonary disease (COPD), a common lung disease, failed a clinical trial.   Its stock was down 20.7% at US$9.14 before Friday's opening bell.

Theravance Biopharma shares down on lung disease trial failure

Theravance Biopharma Inc.'s stock TBPH, -0.60% tumbled 21% early Friday,ter the biotech said a Phase 4 trial of its Yupelri treatment for patients with severe to very severe Chronic Obstructive Pulmonary Disease, or COPD, failed to meet its main goal. The trial dubled PFIR-2 aimed to show greater improvement in lung function for Yupelri delivered by standard jet nebulizer compared to Spiriva delivered via a dry powder inhaler in adults with COPD.

Theravance Biopharma's stock slides 21% after Phase 4 trial of COPD treatment fails to meet main goal

DUBLIN , Jan. 5, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced results from the Phase 4 PIFR-2 study of YUPELRI® (revefenacin) inhalation solution, the only once-daily, nebulized long-acting muscarinic antagonist (LAMA) approved in the U.S. for maintenance treatment of COPD. The PIFR-2 study aimed to demonstrate greater improvement in lung function for YUPELRI delivered via standard jet nebulizer compared to Spiriva® (tiotropium) delivered via a dry powder inhaler (Spiriva® HandiHaler®) in adults with severe to very severe COPD and suboptimal peak inspiratory flow rate (PIFR).

Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Arrival Group

Bank of Hawaii

Harrow Health Inc

Omeros

PAR Technology

Trupanion

While the concept of short-squeeze stocks has been all the rage throughout most of the pandemic-disruption cycle, we may have been doing this all wrong. Rather, it's time to address this speculative practice under a three-dimensional lens.

7 Short-Squeeze Stocks That Are Screaming for Speculation

Enters into Cooperation Agreement with Shareholder Irenic Capital Reaffirms Intention to Return All Excess Capital to Shareholders and Maximize Shareholder Value DUBLIN , Dec. 21, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance" or the "Company") (NASDAQ: TBPH) today announced the appointment to its Board of Directors of Jeremy Grant, who serves as a Special Advisor to Irenic Capital Management LP ("Irenic"). With the addition of Mr.

Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors

DUBLIN , Dec. 18, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that members of its management team including Rick E Winningham, CEO, and Aziz Sawaf, CFO, will hold investor meetings during the 42nd Annual J.P. Morgan Healthcare Conference, January 8-11, 2024, in San Francisco, CA.

Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference

Theravance Bio (TBPH) Up 2.5% Since Last Earnings Report: Can It Continue?

DUBLIN , Nov. 16, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that a new, anchor-based analysis of ampreloxetine data in neurogenic orthostatic hypotension (nOH) will be presented at the 34th International Symposium on The Autonomic Nervous System, a meeting of the American Autonomic Society (AAS), taking place November 15-18, 2023, in Rio Grande, Puerto Rico.  Anchor-based analyses help establish thresholds used to interpret the clinical meaningfulness of changes in patient-reported outcomes measures such as the Orthostatic Hypotension Questionnaire (OHQ).

Theravance Biopharma to Present New Ampreloxetine Data at the 34th International Symposium on The Autonomic Nervous System

DUBLIN , Nov. 15, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference Tuesday, November 28 at 1:45 pm EST (10:45 am PST/6:45 pm GMT) and will be hosting in-person meetings with the investment community at the conference. A Webcast of the event may be accessed by visiting Theravance.com, under the Investors section: Presentations and Events.

Theravance Biopharma to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Viatris

Top-line results from Phase III study in China demonstrate the efficacy and safety profile of YUPELRI in patients with COPD PITTSBURGH and DUBLIN , Nov. 13, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced positive results from the YUPELRI® (revefenacin) Phase III placebo-controlled clinical trial conducted in China assessing the efficacy and safety of YUPELRI, a once-daily nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of patients with COPD. Top-line results showed that YUPELRI met its primary efficacy endpoint demonstrating a statistically significant increase in trough FEV1 (forced expiratory volume in one second) versus placebo.

Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

Thervance (TBPH) incurs a narrower-than-expected loss in the third quarter of 2023. Revenues marginally beat estimates.

Theravance's (TBPH) Q3 Loss Narrows, Revenues Beat Marginally

Theravance Biopharma, Inc. (TBPH) Q3 2023 Earnings Call Transcript

Q3 2023 YUPELRI® (revefenacin) net sales, recognized by Viatris, increased 9% from Q3 2022, reaching an all-time high of $58.3 million 1 Progress made towards the achievement of non-GAAP profitability, with Q3 2023 GAAP Net Loss of $9.0 million and Non-GAAP Loss of $0.7 million 2 Company expects to complete $325 million capital return program by year-end, having returned $30.8 million via share repurchases during Q3 2023 and $294.6 million since inception through quarter end Áine Miller, Ph.D. promoted to SVP of Development; Richard A.

News for Theravance Biopharma Stock (TBPH)